Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

BIORESTORATIVE THERAPIES, INC.

Filed: May 26, 2026CIK: 301341024
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

BioRestorative Therapies extended employment agreements with President/CEO Lance Alstodt and CFO Robert Kristal through May 27, 2029, maintaining their current compensation structure to ensure leadership stability.

Key Takeaways

Lance Alstodt (President, CEO, Chairman) secured a three-year employment extension with an annual salary of $600,000

Robert Kristal (CFO) extended his agreement through May 2029 with an annual salary of $350,000

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 26, 2026
Item5.02
CategoryExecutive Change
CIK301341024
Accession #001-37603
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
leadership transitionmaterial agreement

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings